
DRAK1 Antibody

| Pakkit Pakulanal | | | | | | |
|--|--|--|------------|--|------|-----------------|
| Rabbit Polyclo | | ad P | Protein ID | NP_004751.2 | | S ma |
| Antigen Affinity Purified Catalog No. A302–679A | | | GenelD | 9263 | D | <u></u> |
| Lot No. | | 679A-1 | Jeneid | 5205 | B | ETHYL |
| | | | | | LABC |) RATORIES, INC |
| | | WB, IP, IHC | | | | |
| | | Human | | | | |
| PRESUMED REACTIVITY | | Based on 100% sequence identity, this antibody is predicted to react with Rabbit | | | | |
| AMOUNT | | 100 µl | | | | |
| CONCENTRATION | | 200 µg/ml | | | | |
| STORAGE/SHELF LIFE | | 2 - 8° C / 1 year from date of receipt | | | | |
| PHYSICAL STATE | | | | | | |
| BUFFER | | Tris-buffered Saline containing 0.1% BSA and 0.09% Sodium Azide | | | | |
| ISOTYPE | | IgG | | | | |
| ORIGIN | | USA | | | | |
| PRODUCTION PROCEDURES | | Antibody was affinity purified using an epitope specific to DRAK1 immobilized on solid support. | | | | |
| | | The epitope recognized by A302–679A maps to a region between residue 354 and 414 of human DAP kinase-related apoptosis-inducing protein kinase 1 using the numbering given in entry NP_004751.2 (GeneID 9263). | | | | |
| | | Antibody concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG. | | | | |
| APPLICATIONS | | Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use. | | | | |
| | | Western Blot | 1:2 | ,000 - 1:10,000 | | |
| | | Immunoprecipita | tion 2 – | 5 µg/mg lysate | | |
| | | Immunohistochei | | 00 – 1:1,000. Epitope retr ommended for FFPE tissue | | pH 6.0 is |
| APPLICATION NOTES | | Western blot of immunoprecipitates performed using Normal Pig Serum (Cat. No. S100–020), Goat anti-Rabbit Light Chain HRP Conjugate (Cat. No. A120–113P) and 4–20% SDS–PAGE (link to IP–western blot protocol in Additional Info section below). | | | | |
| IHC HUMAN CONTROLS | | Western blot of lysates performed using standard western blot reagents and 4–20% SDS-PAGE. Breast Carcinoma | | | | |
| ADDITIONAL INFO | | https://www.bethyl.com/product/A302-679A Use the link above to view SDS, a current list of citations, and other product specific information. IP-western blot protocol: https://www.bethyl.com/content/protocol_IP_WB | | | | |


This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc. Eric McIntush, PhD | Chief Scientific Officer Date: June 21, 2019

For in vitro laboratory use only. Not for any clinical, therapeutic or diagnostic use in humans or animals. Not for human or animal consumption. This product may not be resold or modified for resale without the prior written approval of Bethyl Laboratories, Inc. The information provided in this data sheet is believed to be correct but does not purport to be all-inclusive and is intended to be used as a guide. Bethyl Laboratories, Inc. shall not be liable or responsible in any way for use of either this information or the material supplied. Disposal of hazardous material may be subject to federal, state or local laws or regulations.

DRAK1 Antibody



Detection of human DRAK1 by western blot and immunoprecipitation. *Samples:* Whole cell lysate from HeLa (5, 15 and 50 µg for WB; 1 mg for IP, 20% of IP loaded) and HEK293T (T; 50 µg) cells. *Antibodies:* Affinity purified rabbit anti–DRAK1 antibody A302–679A used for WB at 0.04 µg/ml (A) and 0.4 µg/ml (B) and used for IP at 3 µg/mg lysate. DRAK1 was also immunoprecipitated by rabbit anti–DRAK1 antibody A302–678A, which recognizes an upstream epitope. *Detection:* Chemiluminescence with exposure times of 30 seconds (A) and 10 seconds (B).



Detection of human DRAK1 by immunohistochemistry. *Sample:* FFPE section of human lung carcinoma. *Antibody:* Affinity purified rabbit anti- DRAK1 (Cat. No. A302-679A Lot1) used at a dilution of 1:200 (1µg/ml). *Detection:* DAB